Sign inJoin waitlistJoin the waitlist

Hani Kushlaf

Physician · UC Health

Credentials: · · · · · ·

History

OXFORD PHYSICAL THERAPY AND REHABILITATION
2025–Present

Neuromuscular Medicine
Mayo Clinic
2009–2010
Cincinnati Children's Hospital Medical Center
2005–2008
University of Kentucky College of Medicine
2002–2003
University of Tripoli School of Medicine
1998–2002

Research

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
The Lancet Neurology · 2021 · 153 citations
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial
JAMA Neurology · 2023 · 48 citations
Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study
Journal of Neurology · 2022 · 37 citations

Mazen Dimachkie
6 papers
TM
Tahseen Mozaffar
6 papers
Priya Kishnani
5 papers · 3 as a resident
Shafeeq Ladha
5 papers
PC
Paula Clemens
4 papers
Thomas Lloyd
4 papers
Conrad Weihl
3 papers
Cuixia Tian
3 papers
David Walk
3 papers
John Day
3 papers
OG
Ozlem Goker-Alpan
3 papers
Yuebing Li
3 papers

Clinical trials

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2033
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Site PI · Recruiting · Phase 3
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2024–2030